John P Vasilakos
Overview
Explore the profile of John P Vasilakos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mullins S, Vasilakos J, Deschler K, Grigsby I, Gillis P, John J, et al.
J Immunother Cancer
. 2019 Sep;
7(1):244.
PMID: 31511088
Background: Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically "cold" tumors, tumor-resident innate immune cell activation may be required...
2.
Dowling D, van Haren S, Scheid A, Bergelson I, Kim D, Mancuso C, et al.
JCI Insight
. 2017 Mar;
2(6):e91020.
PMID: 28352660
Infection is the most common cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, newborns fail to respond optimally to...
3.
Fatehchand K, Ren L, Elavazhagan S, Fang H, Mo X, Vasilakos J, et al.
J Biol Chem
. 2015 Dec;
291(8):3895-904.
PMID: 26694610
Monocytes and macrophages are critical for the effectiveness of monoclonal antibody therapy. Responses to antibody-coated tumor cells are largely mediated by Fcγ receptors (FcγRs), which become activated upon binding to...
4.
Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, et al.
J Immunol
. 2015 Feb;
194(6):2786-95.
PMID: 25667415
FcγRs are critical mediators of mAb cancer therapies, because they drive cytotoxic processes upon binding of effector cells to opsonized targets. Along with NK cells, monocytes are also known to...
5.
Sabado R, Pavlick A, Gnjatic S, Cruz C, Vengco I, Hasan F, et al.
Cancer Immunol Res
. 2015 Jan;
3(3):278-287.
PMID: 25633712
The Toll-like receptor (TLR) 7/8 agonist resiquimod has been used as an immune adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given...
6.
Singh M, Khong H, Dai Z, Huang X, Wargo J, Cooper Z, et al.
J Immunol
. 2014 Sep;
193(9):4722-31.
PMID: 25252955
Intratumoral immune activation can induce local and systemic antitumor immunity. Imiquimod is a cream-formulated, TLR7 agonist that is Food and Drug Administration approved for the treatment of nonmelanoma skin cancers,...
7.
Zhao B, Vasilakos J, Tross D, Smirnov D, Klinman D
J Immunother Cancer
. 2014 Jul;
2:12.
PMID: 24982761
Background: The TLR7/8 agonist 3M-052 and the TLR9 agonist CpG ODN both trigger innate immune responses that support the induction of tumor-specific immunity. Previous studies showed that these agonists used...
8.
Bose N, Wurst L, Chan A, Dudney C, LeRoux M, Danielson M, et al.
Glycobiology
. 2014 Jan;
24(4):379-91.
PMID: 24440830
β-Glucans possess broad immunomodulatory properties, including activation of innate immune functions such as oxidative burst activity. The differential roles of complement receptor type 3 (CR3) and Dectin-1, the known β-glucan...
9.
Bose N, Chan A, Guerrero F, Maristany C, Qiu X, Walsh R, et al.
Front Immunol
. 2013 Aug;
4:230.
PMID: 23964276
The immunomodulatory properties of yeast β-1,3/1,6 glucans are mediated through their ability to be recognized by human innate immune cells. While several studies have investigated binding of opsonized and unopsonized...
10.
Vasilakos J, Tomai M
Expert Rev Vaccines
. 2013 Jul;
12(7):809-19.
PMID: 23885825
Small molecule Toll-like receptor (TLR) 7/8 agonists have demonstrated potential as vaccine adjuvants, since they directly activate APCs and can enhance both humoral and cellular immune responses, especially Th1 responses....